A Phase 4 interventional study of Statin and methylprednisolone in Sudden Sensorineural Hearing Loss, sponsored by Northwestern University. Terminated at 1 site in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-29.
Sponsored by Northwestern University · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Hearing Loss, Sudden with a site in United States — 1 open to participants now, 1 under way, none of them phase 3. Hearing Loss, Sudden · United States.
Among the 12 studies in Hearing Loss, Sudden with a site in United States, this one is the 9th largest by enrollment of the 11 interventional ones that give a count, is the only one that started in 2023, is the only one in phase 4, and was the 9th registered.
66 studies on the registry are indexed under Hearing Loss, Sudden; 25 are open to participants now.
Browse Hearing Loss, Sudden studies →1 of the 12 studies in Hearing Loss, Sudden with a site in United States is open now. Recruiting first, the newest first:
Truway Health, Inc. · Sites in United States
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 10 Hearing Loss, Sudden studies recruiting now, 3 (30%) set no upper age limit and 5 (50%) stop at 75 or younger; none take children under 18; none take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 6 · Phase 3 1 · Phase 4 1
First in 2004; this study’s year is marked. 1 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 3 is below the median of 72 across 49 interventional studies indexed under Hearing Loss, Sudden.
Median enrollment 30 across the 11 interventional studies, 78 across the 1 observational. Of the 10 that completed or were terminated, 6 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 12 have an industry lead sponsor. The 8 most frequent:
Northwestern University is the lead sponsor of 1,424 studies on the registry; 199 are open to participants now.
Of its 105 completed or terminated interventional studies of FDA-regulated products, 78 (74%) have results posted.
Northwestern University has 1 study filed under Hearing Loss, Sudden — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 12 studies in Hearing Loss, Sudden with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A small clinical trial for idiopathic sudden sensorineural hearing loss (ISSNHL). Will the addition of an oral statin to the standard treatment (oral methylprednesolone and the salvage therapy of intratympanic dexamethasone) improve the treatment outcome for patients with ISSNHL? This study will compare the two treatments and quantitatively evaluate hearing and speech discrimination and have the patients subjectively evaluate tinnitus.
After being informed about the study and potential risks, all patients diagnosed with idopathic sudden sensorineural hearing loss who do not meet the exclusion criteria and do meet the inclusion criteria, and who give written informed consent will be enrolled in the trial. A standard treatment for ISSNHL (oral methyprednisolone) will be given to half of the patients and the other half of the patients will receive the standard treatment plus either a placebo or a 7-day course of an HMG-CoA reductase inhibitor (a statin). Patients will return for follow up, the timing and further treatment of which will be determined by the response to the drugs. At each appointment, the patients will see the medical professional, have a hearing test, a speech in noise test, and self evaluate for tinnitus. If there is no improvement after 2 weeks, patient will be offered up to two intratympanic doses of dexamethasone, 10 days apart. This is a randomized, double-blind prospective study. Randomization of males will be separate from that of females.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
COVID-19 immunization within the last 30 days Patients that medically cannot be treated with corticosteroids or statins or that the physician feels have possible coexisting problems that would cause participation in the study to be unsafe
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Methylprednisolone+statin (identity and dose to be determined before Trial Begins) Oral methyprednisolone, tapering dose over 11 days, beginning at 16 mg 4 x a day; Oral statin 1 dose per day for 7 days, beginning with the first dose of methylprednisolone: If no improvement after two weeks, offer up to 2 doses intratympanic dexamethasone (10 mg/cc) 10 days apart.
Drug: Statin · Drug: methylprednisolone · Drug: dexamethasone
Methylprednisolone+ placebo. Oral methyprednisolone, tapering dose over 11 days, beginning at 16 mg 4 x a day; Oral placebo 1 dose per day for 7 days, beginning with the first dose of methylprednisolone If no improvement after two weeks, offer up to 2 doses intratympanic dexamethasone (10 mg/cc) 10 days apart.
Drug: methylprednisolone · Drug: dexamethasone · Drug: Placebo
Oral dose to be taken with methylprednisolone
Also known as: HMG-coA reductase Inhibitor
oral dose, standard of care
Also known as: medrol
Drug for intratympanic administration
Also known as: decadron
Capsule the same as for statins but without statin
Articulation Index
Estimates how much of normal conversational speech is audible to that ear. Max score is 100%, min score is 0%
Time frame: 2 weeks, 4 weeks, 6 weeks
Word Recognition Score
Measures how many words you correctly repeat when speech is presented at an audible level. * 90-100% = Excellent * 80-89% = Good * 70-79% = Fair * Below 70% = Significant difficulty
Time frame: 2 weeks, 4 weeks, 6 weeks
Tinnitus Handicap Inventory (THI)
Tinnitus Handicap Inventory (THI) is a scale which measures severity of tinnitus. Minimum score is 0 and maximum score is 100. A higher score indicates greater severity of symptoms. Additionally, the numerical scores are divided into the following grades: Grade 1 (Slight): 0-16 Grade 2 (Mild): 18-36 Grade 3 (Moderate): 38-56 Grade 4 (Severe): 58-76 Grade 5 (Catastrophic): 78-100
Time frame: 2 weeks, 6 weeks
Patients were recruited from the Otolaryngology Practice at Northwestern University. Some were recruited by a website description of the study.
| Milestone | Statin | Placebo |
|---|---|---|
| Started | 2 | 1 |
| Completed | 2 | 1 |
| Not completed | 0 | 0 |
Estimates how much of normal conversational speech is audible to that ear. Max score is 100%, min score is 0%
| percentage of speech sounds | Statin | Placebo |
|---|---|---|
| 2 weeks Right ear Male | 86 (86 to 86) | — |
| 2 weeks Left ear Male | 100 (100 to 100) | — |
| 4 weeks Right ear Male | 93 (93 to 93) | — |
| 4 weeks Left ear Male | 100 (100 to 100) | — |
| 6 weeks Right ear Male | 100 (100 to 100) | — |
| 6 weeks Left ear Male | 100 (100 to 100) | — |
| 2 weeks Right ear Female | 100 (100 to 100) | 100 (100 to 100) |
| 2 weeks Left ear Female | 37 (37 to 37) | 100 (100 to 100) |
| 4 weeks Right ear Female | 100 (100 to 100) | 100 (100 to 100) |
| 4 weeks Left ear Female | 80 (80 to 80) | 100 (100 to 100) |
| 6 weeks Right ear Female | 100 (100 to 100) | 100 (100 to 100) |
| 6 weeks Left ear Female | 99 (99 to 99) | 99 (99 to 99) |
Measures how many words you correctly repeat when speech is presented at an audible level. * 90-100% = Excellent * 80-89% = Good * 70-79% = Fair * Below 70% = Significant difficulty
| percentage of words | Statin | Placebo |
|---|---|---|
| 2 weeks Right ear Male | 96 (96 to 96) | — |
| 2 weeks Left ear Male | 100 (100 to 100) | — |
| 4 weeks Right ear Male | 100 (100 to 100) | — |
| 4 weeks Left ear Male | 100 (100 to 100) | — |
| 6 weeks Right ear Male | 100 (100 to 100) | — |
| 6 weeks Left ear Male | 100 (100 to 100) | — |
| 2 weeks Right ear Female | 100 (100 to 100) | 100 (100 to 100) |
| 2 weeks Left ear Female | 88 (88 to 88) | 100 (100 to 100) |
| 4 weeks Right ear Female | 100 (100 to 100) | 100 (100 to 100) |
| 4 weeks Left ear Female | 68 (68 to 68) | 96 (96 to 96) |
| 6 weeks Right ear Female | 100 (100 to 100) | 100 (100 to 100) |
| 6 weeks Left ear Female | 100 (100 to 100) | 100 (100 to 100) |
Tinnitus Handicap Inventory (THI) is a scale which measures severity of tinnitus. Minimum score is 0 and maximum score is 100. A higher score indicates greater severity of symptoms. Additionally, the numerical scores are divided into the following grades: Grade 1 (Slight): 0-16 Grade 2 (Mild): 18-36 Grade 3 (Moderate): 38-56 Grade 4 (Severe): 58-76 Grade 5 (Catastrophic): 78-100
| score on a scale | Statin | Placebo |
|---|---|---|
| 2 weeks Male | 0 (0 to 0) | — |
| 6 weeks Male | 0 (0 to 0) | — |
| 2 weeks Female | 20 (20 to 20) | 16 (16 to 16) |
| 6 weeks Female | 4 (4 to 4) | 0 (0 to 0) |
Collected over Until the end of the study (up to 4 months). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Statin | 0/2 (0%) | 0/2 (0%) | 0/2 (0%) |
| Placebo | 0/1 (0%) | 0/1 (0%) | 0/1 (0%) |
| Age, Categorical(Participants) | Statin | Placebo | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 2 | 1 | 3 |
| >=65 years | 0 | 0 | 0 |
| Sex: Female, Male(Participants) | Statin | Placebo | Total |
|---|---|---|---|
| Female | 1 | 1 | 2 |
| Male | 1 | 0 | 1 |
| Race and Ethnicity Not Collected(Participants) | Statin | Placebo | Total |
|---|---|---|---|
| Count of participants | — | — | 0 |
| Region of Enrollment(Participants) | Statin | Placebo | Total |
|---|---|---|---|
| United States | 2 | 1 | 3 |
| Air Conduction Pure Tone Average(dB HL) | Statin | Placebo | Total |
|---|---|---|---|
| Right ear Males | 73 (73 to 73) | — | 73 (73 to 73) |
| Left ear Males | 15 (15 to 15) | — | 15 (15 to 15) |
| Right ear Females | 10 (10 to 10) | 12 (12 to 12) | 11 (10 to 12) |
| Left ear Females | 72 (72 to 72) | 80 (80 to 80) | 76 (72 to 80) |
| Bone Conduction Pure Tone Average(dB HL) | Statin | Placebo | Total |
|---|---|---|---|
| Right ear Males | 67 (67 to 67) | — | 67 (67 to 67) |
| Left ear Males | 13 (13 to 13) | — | 13 (13 to 13) |
| Right ear Females | 10 (10 to 10) | 2 (2 to 2) | 6 (2 to 10) |
| Left ear Females | 73 (73 to 73) | 67 (67 to 67) | 70 (67 to 73) |
| Articulation Index(percentage) | Statin | Placebo | Total |
|---|---|---|---|
| Right ear Male | 3 (3 to 3) | — | 3 (3 to 3) |
| Left ear Male | 100 (100 to 100) | — | 100 (100 to 100) |
| Right ear Female | 100 (100 to 100) | 100 (100 to 100) | 100 (100 to 100) |
| Left ear Female | 0 (0 to 0) | 0 (0 to 0) | 0 (0 to 0) |
| Tinnitus Handicap Inventory (THI)(score on a scale) | Statin | Placebo | Total |
|---|---|---|---|
| Male | 0 (0 to 0) | — | 0 (0 to 0) |
| Female | 24 (24 to 24) | 24 (24 to 24) | 24 (24 to 24) |
1 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — Only unidentified data will be shared
Ran from Feb 2023 to primary completion in Oct 2025, 32 months.
Results were first posted in Oct 2026, 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is terminated, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Statins